Can NeuroOne Medical Technologies (NASDAQ:NMTC) Drive the Shift from Science Fiction to Science Fact

Today there is a massive $13.6 billion neurostimulation devices market developing for the ongoing study of the vast arrays of the brain’s neural connections. (1) The diagnostic electrode technology currently used to detect neurological disorders is the same that was developed way back in the 1960s. (2) This is where NeuroOne Medical Technologies (NASDAQ:NMTC) comes into play.

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders that may improve patient outcomes and reduce procedural costs.

Mayo Clinic began testing NeuroOne’s technology in preclinical models and clinical research in 2015 and is presently a top shareholder. (3) NeuroOne Evo electrode product line is complementary to Zimmer Biomet’s ROSA ONE Brain platform used in minimally invasive neurosurgeries. (3) NeuroOne has received FDA approval for their Evo Cortical and sEEG Electrodes. (4) This innovative company is behind the scenes bringing what once could be considered science-fiction-inspired technologies to the brink of creation or they already have it in development. And thanks to NeuroOne’s strategic partnerships they expect their technologies to be widely adopted in the near future. Click HERE to read more about why The Future of Neuroscience is Built on This Thin Film Electrode Technology

Other companies in NeuroOne Medical Tech’s space includes ENDRA Life Sciences (NASDAQ:NDRA), Second Sight Medical (NASDAQ:EYES), Bluejay Diagnostics (NASDAQ:BJDX), Motus GI Hldgs (NASDAQ:MOTS), and Tivic Health Systems (NASDAQ:TIVC). It could be interesting to research if Tesla’s (NASDAQ:TSLA) co-founder Elon Musk’s company Neuralink and NeuroOne Medical Technologies (NASDAQ:NMTC) have anything in common. As always conduct your own due diligence.

Sources:

Source 1: https://www.gminsights.com/pressrelease/neurostimulation-devices-market-size

Source 2: https://n1mtc.com/investorsSource

Source 3: https://seekingalpha.com/article/4470806-neuroone-nmtc-stock-thin-film-electrodes-neurological-conditions

Source 4: https://www.mpo-mag.com/contents/view_breaking-news/2021-12-08/fda-clears-neuroone-medical-technologies-evo-seeg-electrode/

Additional Sources:

https://www.mayoclinic.org/about-mayo-clinic

https://www.yahoo.com/now/neuroone-medical-technologies-corporation-announces-130000582.html

https://www.healthaffairs.org/doi/10.1377/hlthaff.2020.01118

For consideration of being featured on WallstreetPR, contact: Editor@Wallstreetpr.com

Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any content posted on our website is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. WallStreetPR strongly recommends you consult a licensed or registered professional before making any investment decision. Neither WallStreetPR.com nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WallStreetPR often gets compensated for advertisement services that are disclosed on our disclaimer located at WallStreetPR.com/Disclaimer.

Published by Alan Masterson

Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@wallstreetpr.com) or his Google+ page (https://plus.google.com/103338576216002376250).